NEW YORK, January 24, 2017 /PRNewswire/ --
For today, Stock-Callers.com scans the following Biotechnology companies: Genetic Technologies Ltd (NASDAQ: GENE), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Egalet Corp. (NASDAQ: EGLT). These equities are part of the Healthcare sector which was moderately lower on Monday, January 23rd, 2017, with the NYSE Health Care Index dropping about 0.3%, while shares of health care companies in the S&P 500 also were down 0.3% as a group. These stocks research reports can be downloaded now by simply registering for free at:
On Monday, shares in Fitzroy, Australia-based Genetic Technologies Ltd recorded a trading volume of 253,872 shares. The stock ended the session 3.57% lower at $1.08. The Company's shares are trading 13.14% below their 50-day moving average. Moreover, shares of Genetic Technologies, which operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia, have a Relative Strength Index (RSI) of 43.21.
On December 01st, 2016, Genetic Technologies announced that it has entered into a definitive agreement with US institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 4,800,000 American Depositary Shares (ADS), each representing one hundred and fifty of the Company's Ordinary Shares, at a weighted average price of $1.25 per ADS. The Company will receive gross proceeds of approximately USD 6.0 million, before deducting customary offering expenses. Your complete research report on GENE can be retrieved for free at:
Bothell, Washington headquartered Alder Biopharmaceuticals Inc.'s stock closed the day 4.05% lower at $20.15, with a total trading volume of 435,874 shares. The Company's shares are trading 15.63% below their 50-day moving average. Shares of the Company, which discovers, develops, and commercializes therapeutic antibodies in the US and Australia, have an RSI of 38.72. ALDR free report is just a click away at:
Shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. recorded a trading volume of 96,431 shares. The stock ended yesterday's trading session flat at $1.90. The Company's shares have advanced 8.57% on an YTD basis. The stock is trading above its 50-day moving average by 3.37%. Furthermore, shares of BioDelivery Sciences International, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 53.40.
On January 13th, 2017, MonoSol Rx announced that it filed a patent infringement case against BioDelivery Sciences International, Inc. (BDSI) for infringement of US Patent No. 8,765,167 (the '167 patent), which is entitled "Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions." The '167 patent has a priority date as far back as 2001, as well as additional priority in 2005. The complaint was filed in the US District Court for the District of New Jersey. The complaint asserts that the manufacture, marketing and sale of BDSI's BELBUCA™ (buprenorphine) buccal film product infringes the '167 patent. Specifically, the complaint asserts infringement of claims 13, 33, 39, 45, 52, 66, 73, 83, 89, 95-98, 100-103, 105, 107, 108, 117, and 118 of the '167 patent. Sign up for your complimentary research report on BDSI at:
Wayne, Pennsylvania headquartered Egalet Corp.'s stock finished Monday's session 6.77% higher at $5.36. A total volume of 1.01 million shares was traded, which was above their three months average volume of 861,560 shares. The Company's shares are trading below their 200-day moving average by 21.02%. Additionally, shares of Egalet, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have an RSI of 33.74.
On January 18th, 2017, Egalet announced the closing of the second $40 million tranche of the $80 million secured debt financing announced August 31, 2016. The Company stated that the second tranche was triggered by the approval from the US Food and Drug Administration of ARYMO™ ER (morphine sulfate) abuse-deterrent, extended-release tablets C-II on January 9th, 2017. In addition, the company announced that it will issue options to purchase stock to employees in Egalet's recently internalized salesforce. Register for free on Stock-Callers.com and download the latest research report on EGLT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA